First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO® UncategorizedBy Charlotte Maddalena22 June 2022
ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension UncategorizedBy Charlotte Maddalena9 June 2022
Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer UncategorizedBy Charlotte Maddalena7 June 2022
